Gilenya and Tasigna drive new product growth at Novartis
19 July 2011
Eleanor Malone
Please Login to read the full article.
19 July 2011
Eleanor Malone
eleanor.malone@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- Patient access scheme prompts NICE U-turn on Novartis' Tasigna, while BMS will appeal against no for Sprycel
- Novartis trumps Bristol-Myers Squibb at NICE for chronic CML
- Pfizer's two cancer candidates accepted for EMA review
- NICE stands by Novartis' cut-price Tasgina over BMS' Sprycel in second-line CML
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
